• About Us
  • Overview
  • Strategy
  • Management >
    • Board of Directors
    • Senior Management
  • Scientific Advisory Board
  • Job Opportunities
• Clinical Trials
  • Overview
• Products
  • Advanced Pipeline >
    • TroVax^®
    • ProSavin^®
    • Hi-8 MEL^®
    • MetXia^®
    • RetinoStat^®
  • Early-stage Pipeline >
    • StarGen^®
    • MoNuDin^®
    • SMN-1G
    • Innurex^®
    • ReQuinate^®
    • ImmStat^®
    • EndoAngio-GT
    • Targeted Antibody
• Technology
  • Gene Delivery Technologies
  • Gene Discovery and Target Validation
  • Antibody Delivery
  • Hypoxia Response Element
• Collaborations
  • Corporate Partnerships
  • Technology Licence Agreements
  • Scientific Collaborations and Advisors
• Investors
  • Financing History
  • Accounts
  • Share Price
  • Presentation >
    • Interim Results August 2008
    • Annual General Meeting May 2008
    • Annual Results March 2007
  • Web Casts
  • Announcements
  • Shareholder Meetings
  • Contact
• News
  • Announcements
  • Events
  • Media Coverage
• Contact Us
  • UK >
    • Contacts
    • Directions
    • Map
  • USA >
    • Contacts
    • Directions
    • Map

CORPORATE MISSION
Oxford BioMedica’s mission is to be the leading company in the development of gene-based medicines for the treatment of diseases that have an unmet medical need and to retain a significant economic stake in the commercialisation of its products and technologies. Oxford BioMedica operates to high standards of integrity in its dealings with all parties, including shareholders, employees, patients, healthcare professionals, partners, licensees and the wider community, and seeks significant returns for shareholders through the achievement of scientific and operational excellence.

CORPORATE STRATEGY
Oxford BioMedica’s corporate strategy is to create a profitable biopharmaceutical company. Internal research and development activities have established a broad pipeline, based on proprietary technologies, that addresses diseases with unmet medical need and that potentially offer substantial commercial return. Part of the strategy pursued by the management team is to ensure that the Company’s value is not dependent on a single candidate but, rather, derives from a portfolio of candidates. While spreading the risk over a relatively diverse portfolio, the management has maintained its main therapeutic focus in the areas of oncology and neurotherapy.

Oxford BioMedica is also pursuing development opportunities outside of its core therapeutic focus where this can be achieved through collaborations and external financing. In addition, the Company has an active licensing strategy that provides third party access to its intellectual property for non-exclusive research use or exclusive access for specific applications.

There are inherent challenges in bringing products from the laboratory to the clinic and Oxford BioMedica has established appropriate expertise to manage the process. In addition to its technical research skill-base, the Company has in-house clinical, regulatory and manufacturing know-how.

The Company’s broad commercial strategy is to secure development and commercialisation partners for its in-house products following proof of principle in clinical studies. However, in such agreements, the Company may seek to retain the rights or options to commercialise its products in certain territories. Similarly, the Company may decide to invest in later stage clinical trials if the management concludes that it has adequate resources and that the risk is acceptable in relation to the potential increased return for shareholders. The Company would consider licensing its products at the preclinical stage only if sufficiently attractive terms could be negotiated. The objective of the Company’s commercial strategy is to maximise shareholder value by balancing near-term resource requirements and long-term benefit from product commercialisation.

Website by College Hill - Life Sciences